Several strategies have been studied in preclinical tumor models to interfere with NRP-1 in the TME, ranging from genetic strategies, such as modification of cancer cells to express soluble NRP-1 or downregulate NRP-1 [27,28,29,30,31,32,33,34], to the use of mAbs that block NRP-1 [6,35,36,37,38,39]. Here, NRP1 is linked to neoplasm.